Subscribe To
Adaptive announces launch of epic integration for clonoseq®
The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers SE...
September 13, 2023, 11:30 am
Adaptive biotechnologies: getting closer to the 'buy zone'
Shares of diagnostics and drug discovery concern Adaptive Biotechnologies Corporation have crashed over 90% as the commercial-stage concern struggles ...
July 7, 2023, 2:00 pm
Adaptive biotechnologies highlights new data showcasing the clinical utility of clonoseq® mrd testing in patients with blood cancers at the 64th ash annual meeting
Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-making More than 3...
December 10, 2022, 3:00 pm
Adaptive biotechnologies and collaborators to present more than 30 abstracts demonstrating the clinical utility and benefit of clonoseq® mrd testing in blood cancer patients at 2022 ash annual meeting
SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data fro...
December 5, 2022, 7:30 am
Adaptive biotechnologies: becoming the next big thing in the biotech industry
Adaptive Biotech product 'clonoSEQ' is the first MRD test cleared by FDA for multiple myeloma, CLL, and B-ALL. The company's "T-Detect" is the first-e...
April 15, 2022, 7:58 am
Adaptive biotechnologies to lay off ~12% of its workforce, names tycho peterson as cfo
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) will be organized around two distinct business areas - Minimal Residual Disease (MRD) and Immune ...
March 9, 2022, 10:37 am